Elicio Therapeutics, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Boston, MA. Its latest filed balance sheet (2025-12-31) shows total assets of $23 million (its filed statements).
Pre-revenue companyPharmaceutical PreparationsBoston, MAfilings since 20145 of 9 filed, 4 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.5 out of ten, 5 of 9 metrics filed and 4 estimated: past 2.5 out of ten, present 2.8 out of ten, future 4.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 4.5 out of ten. 2 warning events since 2017; the latest 2023-06-02. 45th percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 2.9 out of ten. -10.6% a year over 3 filed years; profitable in 0 of 3. 29th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 0.7 out of ten. CrossAssetData estimate 0.7/10, confidence 35 of 100 (one part). 7th percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 1.9 out of ten. ROE -2419%: lost 2419¢ per shareholder dollar. Leverage 94%: owes 94¢ per asset dollar. 19th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 2.7 out of ten. bottom 27% of 314 in its family; net margin -1225.9%. 27th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 4.1 out of ten. CrossAssetData estimate 4.1/10, confidence 35 of 100 (one part). 41st percentile among 414 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Room to expand (future): 6.0 out of ten. CrossAssetData estimate 6.0/10, confidence 35 of 100 (one part). 60th percentile among 479 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Growth drivers (future): 3.3 out of ten. bottom 33% of 307 in its family for growth drivers. 33rd percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 5.3 out of ten. CrossAssetData estimate 5.3/10, confidence 20 of 100 (family median). 50th percentile among 235 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
The filing record
Newest annual report: Form 10-K filed 2026-03-12 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-13 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-13 (on EDGAR). Newest filing: Form DEF 14A, 2026-10-09. Filings on record since 2014. Read from EDGAR 2026-10-12.
Who runs it
Venkatesan, Jay (President and Chief Executive Officer and Director); Connelly, Robert (CEO, President and Director); Haqq, Christopher (Executive Vice President, Head of R&D and Chief Medical Officer); Demuth, Peter (Chief Scientific Officer); Shah, Preetam (Chief Strategy and Financial Officer); Adams, Julian (director); Ashe, Carol Gail (director); Chudnovsky, Yekaterina (director); Nissenson, Allen (director); Ruffolo, Robert R (director); and 1 more. 11 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.